UBS's Upgrade of Bristol-Myers Squibb Reflects Confidence in Late-Stage Pipeline and Future Drug Launches.

UBS has upgraded Bristol-Myers Squibb, citing its broad drug pipeline, new clinical trial initiations, and progress on products to ease patent expirations. This reinforces the company's investment narrative, which balances patent risks with future drug launches across oncology, cardiovascular, and neuroscience. The upgrade supports confidence in near-term catalysts, but the biggest ongoing risk remains the impact of patent cliffs on drugs like Eliquis and Opdivo.